Saudi CMA grants approval for BaraSeen Medical IPO on Tadawul
Riyadh – Mubasher: The Board of the Capital Market Authority (CMA) has officially sanctioned the registration and initial public offering (IPO) of BaraSeen Medical Company on the Saudi Parallel Market (Nomu).
According to the regulatory announcement issued on 24 June 2026, BaraSeen Medical will float 3.30 million ordinary shares, representing 17.10% of its total share capital, to a specialized segment of the investing public.
The resolution passed by the CMA Board marks a significant step for BaraSeen Medical as it prepares to enter the kingdom’s secondary equity tier.
The IPO is strictly reserved for the category of Qualified Investors, as defined in the Glossary of Defined Terms used in the CMA’s regulations. The classification typically encompasses institutional entities, government-related bodies, and individual investors who meet specific professional and financial criteria, ensuring that the participants in Nomu possess the necessary expertise to navigate its unique investment environment.
In line with standard regulatory procedures, the CMA confirmed that a comprehensive prospectus will be published and made available to the public well in advance of the subscription period. This document will contain essential disclosures regarding the company’s financial position, management structure, and operational risks.
Moreover, the CMA issued a directive to all prospective Qualified Investors to conduct thorough due diligence and independent assessments of the information disclosed in the prospectus.
For investors who find the technical or financial complexities of the prospectus difficult to interpret, the CMA recommends consulting with an authorized financial advisor before committing to any investment decision.
The regulatory body also clarified the nature of its approval, noting that the resolution should not be interpreted as a recommendation to invest in the company or an endorsement of its shares. Instead, the approval serves as a formal confirmation that BaraSeen Medical fulfilled the legal and technical requirements stipulated by the Capital Market Law and its Implementing Regulations.
The CMA’s role remains focused on ensuring market transparency and regulatory compliance rather than evaluating the commercial attractiveness of the offering.
Furthermore, the approval carries a specific timeframe for execution. The CMA Board’s resolution remains valid for a period of six months from the date of issuance.
Should the company fail to complete the offering and subsequent listing on the Nomu platform within this six-month window, the approval will be deemed cancelled. In such an event, the company would be required to reapply for registration and offering should it wish to pursue a public listing at a later date.
The entry of BaraSeen Medical into Nomu reflects the ongoing expansion of the Saudi healthcare sector within the national capital markets.
By utilizing the Nomu platform, the company gains access to capital while adhering to the specific listing requirements tailored for small and medium-sized enterprises. This move aligns with the broader objectives of the Saudi financial sector to diversify the types of companies available to investors and to deepen the liquidity of the Parallel Market.
As the offering moves toward the subscription phase, the market will look to the forthcoming prospectus for a detailed view of the company's valuation and growth strategy.
Source: Mubasher Source: {{details.article.source}}